Bayer IR Newsfeed: EventsBayer IR Newsfeed: Investor News30.07.08: Interim report for the second quarter of 2008- July 30, 2008 Bayer continues its successSales up 3.6 percent to EUR 8,511 million EBITDA before special items increases by 5.0 percent to EUR 1,896 million EBIT before special items improves by 5.3 percent to EUR 1,248 million Full-year guidance for CropScience raised again Group earnings forecast confirmedmehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/971 30.07.08: Venous Blood Clot Prevention after Hip or Knee Replacement Surgery:- July 30, 2008 Bayer's Novel Anticoagulant Rivaroxaban Submitted for Approval in the U.S.Rivaroxaban is first oral anticoagulant to achieve superior efficacy over the twice-daily injection of enoxaparin while maintaining low rates of major bleeding No evidence of safety issues attributable to rivaroxaban after long-term exposuremehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/969 28.07.08: Another milestone for cancer drug from Bayer and Onyx:- July 28, 2008 Nexavar Approved for Treatment of Liver Cancer in China Nexavar is First Approved Systemic Therapy to Treat the Diseasemehr ...http://www.investor.bayer.de/no_cache/en/news/investor-news/investor-news/showNewsItem/967 |